News | October 31, 2025
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
